New diabetes combo pill shows promise in Late-Stage trial
NCT ID NCT05814393
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 3 trial tested whether adding an experimental drug called JW0201 to standard diabetes medications (metformin and empagliflozin) helps lower blood sugar more effectively. The study involved 200 adults with type 2 diabetes whose blood sugar was not well controlled on their current treatment. Participants took either JW0201 or a placebo for 24 weeks, and researchers measured changes in HbA1c, a key blood sugar marker.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JW0201 (an experimental drug added to metformin and empagliflozin)
What this could lead to
If successful, JW0201 could offer a new add-on option to help people with type 2 diabetes achieve better blood sugar control when standard medications are not enough.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The drug may not prove significantly better than placebo, and side effects are possible. It is not a cure and requires ongoing medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kangbuk Samsung Hospital
Seoul, South Korea